Thunnissen et al. [116] pointed out that the current challenges in developing IHC for ALK detection in NSCLC are: 1) tissue preparation, 2) antibody choice, 3) signal enhancement systems, and 4) the optimal scoring system. This evidence concerns the gene ALK and non-small cell lung carcinoma.